<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2 Final//EN">
<HTML>
<HEAD>
     <!-- Created by EDGAR Ease Plus (EDGAR Ease+ 1.6a) -->
     <!-- Project:        I:\CONVER\ny13038.eep                                            -->
     <!-- Rev Number:     8-K                                                              -->
     <!-- Client Name:    Advanced Medical Optics                                          -->
     <!-- Project Name:   ny13020                                                          -->
     <TITLE>8-K</TITLE>
</HEAD>
<BODY>
<BR><BR>


<!-- MARKER FORMAT-SHEET="Head Center 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=BOTTOM>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2><B>UNITED
STATES<BR>SECURITIES AND EXCHANGE COMMISSION<BR>Washington, D.C. 20549</B>  </FONT></TD></TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Head Center 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=BOTTOM>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2><B>FORM 8-K </B> </FONT></TD></TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Head Center 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=BOTTOM>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2><B>CURRENT
REPORT<BR>Pursuant to Section 13 or 15(d) of the<BR> Securities Exchange Act of 1934</B>  </FONT></TD></TR>
</TABLE>
<BR>


<!-- MARKER FORMAT-SHEET="Head Center 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=BOTTOM>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Date
of Report (Date of earliest event reported):&nbsp;&nbsp;June 21, 2004 </FONT></TD></TR>
</TABLE>
<BR>

<TABLE WIDTH="600" BORDER="0" CELLPADDING="0" CELLSPACING="0">
<TR VALIGN="BOTTOM">
     <TD WIDTH="600" ALIGN="CENTER"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">
<B>ADVANCED MEDICAL OPTICS, INC.<!-- Name of Registrant --></B></FONT></TD></TR>
<TR VALIGN="TOP">
     <TD WIDTH="600" ALIGN="CENTER"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">
(Exact name of registrant as specified in its charter)</FONT></TD></TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="8k Cover table 3" FSL="Project" -->
<TABLE WIDTH="600" CELLPADDING="0" CELLSPACING="0" BORDER="0">
<tr Valign=BOTTOM>
<TD WIDTH="33%" ALIGN="CENTER"><Font Face="Times New Roman, Times, Serif" Size=2><B>Delaware</B><!-- State--></font></td>
<TD WIDTH="34%" ALIGN="CENTER"><Font Face="Times New Roman, Times, Serif" Size=2><B>01-31257</B><!-- File No.--></font></td>
<TD WIDTH="33%" ALIGN="CENTER"><Font Face="Times New Roman, Times, Serif" Size=2><B>33-0986820</B><!-- Irs No.--></font></td>
</tr>
<tr Valign=TOP>
<TD ALIGN="CENTER"><Font Face="Times New Roman, Times, Serif" Size=2>(State or other jurisdiction <br>of incorporation)</font></td>
<td ALIGN="CENTER"><Font Face="Times New Roman, Times, Serif" Size=2>(Commission<br>File Number) </font></td>
<TD ALIGN="CENTER"><Font Face="Times New Roman, Times, Serif" Size=2>(IRS Employer<br> Identification No.) </font></td>
</tr>
</table>
<BR>

<TABLE WIDTH="600" BORDER="0" CELLPADDING="0" CELLSPACING="0">
<TR VALIGN="BOTTOM">
     <TD WIDTH="70%" ALIGN="CENTER"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>1700 E. St. Andrew Place<BR>
Santa Ana, CA</B> </FONT></TD>
     <TD WIDTH="5%"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp;</FONT></TD>
     <TD WIDTH="20%" ALIGN="left"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp;&nbsp;&nbsp;<B>92705</B> </FONT></TD></TR>
<TR VALIGN="TOP">
     <TD ALIGN="CENTER"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">(Address of principal executive offices)</FONT></TD>
     <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp;</FONT></TD>
     <TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">(Zip Code)</FONT></TD></TR>
</TABLE>
<BR><BR>

<!-- MARKER FORMAT-SHEET="Head Center 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Registrant's telephone number, including area code:&nbsp;&nbsp;<B>(714) 247-8200</B>&nbsp;
<!-- TELEPHONE NO. --></FONT></TD></TR>
</TABLE>
<BR><BR>

<!-- MARKER FORMAT-SHEET="Head Center 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(Former name or former address, if changed since last report)  </FONT></TD></TR>
</TABLE>
<BR>


<!-- MARKER FORMAT-SHEET="Page Break Table" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><HR SIZE=5 NOSHADE COLOR="BLACK">
</TD></TR></TABLE><BR>


<!-- MARKER FORMAT-SHEET="Para Flush Left" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2><B>Item 5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other Events and Regulation FD Disclosure.</B> <BR><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
June 21, 2004, Advanced Medical Optics, Inc. issued a press release, attached hereto as
Exhibit&nbsp;99.1 and by this reference incorporated herein, announcing the results of
the previously announced consent solicitation for its 9&frac14;% Senior Subordinated
Notes due 2010.
</FONT></TD></TR></TABLE><BR>


<!-- MARKER FORMAT-SHEET="Head Left 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD>
<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2><b>Item 7. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.</B><BR><BR>
Exhibit
99.1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Press Release, dated June 21, 2004, issued by
Advanced Medical Optics, Inc. </FONT></TD></TR></TABLE><BR>

<BR>




<!-- MARKER FORMAT-SHEET="Page Break Table" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><HR SIZE=5 NOSHADE COLOR="BLACK">
</TD></TR></TABLE><BR>


<!-- MARKER FORMAT-SHEET="Head Center Bold 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>SIGNATURES </FONT></H1></TD></TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Flush Left" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.  </FONT></TD></TR></TABLE><BR>





<!-- MARKER FORMAT-SHEET="Company Right" FSL="Project" -->
<TABLE WIDTH="600" BORDER="0" CELLSPACING="0" CELLPADDING="0">
  <TR VALIGN="BOTTOM">
    <TD WIDTH="8%"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp; <!-- TYPE "DATE:" HERE--> </FONT></TD>
    <TD WIDTH="44%"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp; </FONT></TD>
    <TD WIDTH="48%"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">ADVANCED MEDICAL OPTICS, INC.<BR>
(Registrant)  </FONT></TD>
  </TR>
</TABLE>
<BR>




<!-- MARKER FORMAT-SHEET="Date By Signature" FSL="Project" -->
<TABLE WIDTH="600" BORDER="0" CELLSPACING="0" CELLPADDING="0">
  <TR VALIGN="BOTTOM">
    <TD WIDTH="8%"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">Date: </FONT></TD>
    <TD WIDTH="39%"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">June 21, 2004 <!-- DATE--> </FONT></TD>
    <TD WIDTH="5%"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp; </FONT></TD>
    <TD WIDTH="5%" VALIGN="TOP"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">By: </FONT></TD>
    <TD WIDTH="43%"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp;<U>&nbsp;/s/ Aimee S. Weisner&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><BR>
Aimee S. Weisner<BR>Corporate Vice President,<BR>
General Counsel and Secretary<!-- NAME --> </FONT></TD>
  </TR>
  <TR VALIGN="TOP">
    <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp; </FONT></TD>
    <TD>&nbsp; </TD>
    <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp; </FONT></TD>
    <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp; </FONT></TD>
  </TR>
</TABLE>



<!-- MARKER FORMAT-SHEET="Page Break Table" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><HR SIZE=5 NOSHADE COLOR="BLACK">
</TD></TR></TABLE><BR>




<!-- MARKER FORMAT-SHEET="Head Center Bold 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>EXHIBIT INDEX </FONT></H1></TD></TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Exhibit Index" FSL="Project" -->
<TABLE WIDTH=600 CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=13%><FONT FACE="Times New Roman, Times, Serif" SIZE=2><B>Exhibit<BR> No.</B> </FONT></TD>
<TD WIDTH=3%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=84%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Exhibit Index" FSL="Project" -->
<TABLE WIDTH=600 CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=13%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 99.1 </FONT></TD>
<TD WIDTH=3%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=84%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Press
Release, dated June 21, 2004, issued by Advanced Medical Optics, Inc. </FONT></TD>
</TR>
</TABLE>
<BR>


<!-- MARKER FORMAT-SHEET="Page Break Table" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><HR SIZE=5 NOSHADE COLOR="BLACK">
</TD></TR></TABLE><BR>


<!-- MARKER FORMAT-SHEET="Head Right 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=RIGHT>
<FONT FACE="Times New Roman, Times, Serif" SIZE=2><B>Exhibit
99.1</B> </FONT></TD></TR>
</TABLE>
<BR>


<!-- MARKER FORMAT-SHEET="Head Right 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=RIGHT>
<FONT FACE="Times New Roman, Times, Serif" SIZE=2><IMG SRC="adv.jpg"> </FONT></TD></TR>
</TABLE>
<BR>




<!-- MARKER FORMAT-SHEET="Head Left Bold 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD>
<H1 ALIGN=LEFT><FONT FACE="Arial, Helvetica, Sans-Serif" SIZE="2">FOR IMMEDIATE RELEASE </FONT></H1></TD></TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang 0" FSL="Project" -->
<TABLE WIDTH=600 CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=20%><FONT FACE="Arial, Helvetica, Sans-Serif" SIZE="2">Investor Contact:</FONT></TD>
<TD WIDTH=80%><FONT FACE="Arial, Helvetica, Sans-Serif" SIZE="2">
Sheree Aronson<BR>
(714) 247-8290<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>sheree.aronson@amo-inc.com</U></FONT></TD>
</TR>
</TABLE>
<BR><BR>




<!-- MARKER FORMAT-SHEET="Para Hang 0" FSL="Project" -->
<TABLE WIDTH=600 CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=20%><FONT FACE="Arial, Helvetica, Sans-Serif" SIZE="2">Media Contact:</FONT></TD>
<TD WIDTH=80%><FONT FACE="Arial, Helvetica, Sans-Serif" SIZE="2">
Steve Chesterman <BR>
(714) 247-8711 <BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>steve.chesterman@amo-inc.com</U></FONT></TD>
</TR>
</TABLE>
<BR><BR>


<!-- MARKER FORMAT-SHEET="Head Center Bold 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><H1 ALIGN=CENTER><FONT FACE="Arial, Helvetica, Sans-Serif" SIZE="2">ADVANCED MEDICAL OPTICS ANNOUNCES <BR>
RESULTS OF CONSENT SOLICITATION<BR>
RELATING TO ITS 9&frac14;% SENIOR SUBORDINATED NOTES DUE 2010
</FONT></H1></TD></TR>
</TABLE>
<BR>


<!-- MARKER FORMAT-SHEET="Para Indent 0" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><FONT FACE="Arial, Helvetica, Sans-Serif" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(SANTA
ANA, CA), June 21, 2004 &#151; Advanced Medical Optics, Inc. (AMO) [NYSE: AVO], today
announced that, as of 5:00 p.m., Eastern Daylight Time, on June 21, 2004 (the "Consent
Date"), it had received tenders and related consents from holders of approximately 99.99%
of the outstanding principal amount of its 9&frac14;% Senior Subordinated Notes due 2010 (CUSIP number 00763MAC2)
(the "Notes") pursuant to its previously announced offer to purchase for cash
(the "Offer") any and all of the $70,000,000 outstanding principal amount of
the Notes and solicitation of consents to certain proposed amendments to the indenture
related to the Notes (the "Consent Solicitation"). The Consent Solicitation
expired on the Consent Date. Pursuant to its terms, the Offer will remain open until
12:00 midnight, Eastern Daylight Time, on July 8, 2004, unless extended or earlier
terminated (the "Expiration Time"). The Offer and the Consent Solicitation is
conditioned upon, among other things, the completion by AMO of financing transactions to
fund consummation of the Offer and the Consent Solicitation.  </FONT></TD></TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Indent 0" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><FONT FACE="Arial, Helvetica, Sans-Serif" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AMO
has received consents necessary to adopt the proposed amendments to the indenture related
to the Notes. Among other things, these amendments would eliminate substantially all of
the indenture&#146;s restrictive covenants and certain events of default contained in the
indenture. The supplemental indenture effecting the proposed amendments will become
operative on the Initial Payment Date, as described below.  </FONT></TD></TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Indent 0" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><FONT FACE="Arial, Helvetica, Sans-Serif" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to the terms and conditions of the Offer and the Consent Solicitation, AMO will pay the
"Total Consideration" to the holders who have validly tendered their Notes and
validly delivered their consents to the proposed amendments on or prior to the Consent
Date. Total Consideration will be determined based upon the pricing formula set forth in
the Offer to Purchase and Consent Solicitation Statement, dated June 9, 2004 (the "Statement"),
pursuant to which the Offer and the Consent Solicitation are being made, with June 22,
2004 being the price determination date. The Total Consideration includes a consent
payment of $30.00 per $1,000 principal amount of Notes (the "Consent Payment"),
and is payable on the applicable payment date.  </FONT></TD></TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Indent 0" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><FONT FACE="Arial, Helvetica, Sans-Serif" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to the terms and conditions of the Offer and the Consent Solicitation, AMO expects to
accept for payment and pay for all Notes that have been validly tendered and not validly
withdrawn on or prior to the Consent Date on or promptly following the first business day
after the Consent Date (the "Initial Payment Date"). AMO will pay to Holders
who validly tender their Notes after the Consent Date, but on or prior to the Expiration
Date, the Total Consideration minus the Consent Payment. Subject to the terms and
conditions of the Offer and the Consent Solicitation, AMO expects to accept for payment
and pay for all Notes that are validly tendered and not validly withdrawn after the
Consent Date, but on or prior to the Expiration Date, on or promptly following the first
business day after the Expiration Date (the "Final Payment Date"). In addition,
AMO may, at its option, elect to accept for payment, and pay for, Notes on interim
payment dates after the Initial Payment Date and before the Final Payment Date. Holders
will also be paid accrued and unpaid interest from the last interest payment date to, but
not including, the applicable payment date.  </FONT></TD></TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Indent 0" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><FONT FACE="Arial, Helvetica, Sans-Serif" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Holders
may not withdraw their tenders or revoke their consents at any time after the Consent
Date.  </FONT></TD></TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Indent 0" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><FONT FACE="Arial, Helvetica, Sans-Serif" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
press release does not constitute an offer to purchase or the solicitation of an offer to
purchase, or a solicitation of consents with respect to the Notes. The Offer and the
Consent Solicitation may only be made in accordance with the terms and subject to the
conditions specified in the Statement and a related Letter of Transmittal and Consent,
which more fully set forth the terms and conditions of the Offer and Consent
Solicitation.  </FONT></TD></TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Indent 0" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><FONT FACE="Arial, Helvetica, Sans-Serif" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lehman
Brothers Inc. is acting as the exclusive dealer manager and solicitation agent, Mellon
Investor Services LLC is acting as the information agent and The Bank of New York is
acting as depositary in connection with the Offer and the Consent Solicitation. Copies of
the Statement,, the Letter of Transmittal and Consent, and other related documents may be
obtained from the information agent at (877) 698-6865. Additional information concerning
the terms of the Offer and Consent Solicitation may be obtained by contacting Lehman
Brothers at (800) 438-3242 (toll free) and (212) 528-7581 (collect).  </FONT></TD></TR>
</TABLE>
<BR>



<!-- MARKER FORMAT-SHEET="Para Indent 0" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><FONT FACE="Arial, Helvetica, Sans-Serif" SIZE="2"><b>About
Advanced Medical Optics</b><BR><BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Advanced
Medical Optics, Inc. is a global leader in the development, manufacturing and marketing
of ophthalmic surgical and eye care products. The company focuses on developing a broad
suite of innovative technologies and devices to address a wide range of eye disorders.
Products in the ophthalmic surgical line include foldable intraocular lenses,
phacoemulsification systems, viscoelastics and related products used in cataract surgery,
and microkeratomes used in LASIK procedures for refractive error correction. AMO owns or
has the rights to such ophthalmic surgical product brands as PhacoFlex&reg;, Clariflex&reg;,
Array&reg; and Sensar&reg; foldable intraocular lenses, the Sovereign&reg; phacoemulsification
system with WhiteStar&#153; technology and the Amadeus&#153; microkeratome. Products in
the contact lens care line include disinfecting solutions, daily cleaners, enzymatic
cleaners and lens rewetting drops. Among the contact lens care product brands the company
possesses are COMPLETE&reg;, COMPLETE&reg; Blink-N-Clean&reg;, COMPLETE&reg; Moisture PLUS&#153;,
Consept&reg;F, Consept&reg; 1 Step, Oxysept&reg; 1 Step, Ultracare&reg;, Ultrazyme&reg;,
Total Care&reg; and blink&#153; branded products. Amadeus is a licensed product of, and a
trademark of, SIS, Ltd.  </FONT></TD></TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Indent 0" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><FONT FACE="Arial, Helvetica, Sans-Serif" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Advanced
Medical Optics, Inc. is based in Santa Ana, California, and employs approximately 2,300
worldwide. The Company has direct operations in about 20 countries and markets products
in approximately 60 countries. For more information, visit the Company&#146;s web site at
www.amo-inc.com.  </FONT></TD></TR>
</TABLE>
<BR>


<!-- MARKER FORMAT-SHEET="Para Indent 0" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><FONT FACE="Arial, Helvetica, Sans-Serif" SIZE="2"><B>Forward-Looking Statements</B><BR><BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
press release contains forward-looking statements about AMO, including those relating to
the terms of the Offer and the Consent Solicitation and whether or not AMO will
consummate the Offer and the Consent Solicitation. All forward-looking statements in this
press release are based on estimates and assumptions and represent AMO&#146;s judgment
only as of the date of this press release. Actual results may differ from current
expectations based on a number of factors including but not limited to changing market
conditions and AMO&#146;s ability to raise sufficient funds to complete the financing to
fund the Offer and the Consent Solicitation. In addition, matters generally affecting the
domestic and global economy, such as changes in interest and currency exchange rates, can
affect AMO&#146;s results. Therefore, the reader is cautioned not to rely on these
forward-looking statements. AMO disclaims any intent or obligation to update these
forward-looking statements.  </FONT></TD></TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Indent 0" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><FONT FACE="Arial, Helvetica, Sans-Serif" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additional
information concerning these and other risk factors may be found in previous financial
press releases issued by AMO. AMO&#146;s public periodic filings with the Securities and
Exchange Commission, including the discussion under the heading "Certain Factors and
Trends Affecting AMO and its Businesses" in AMO&#146;s 2003 Form 10-K filed by AMO
with the Securities and Exchange Commission (the "Commission") on March 12,
2004 and AMO&#146;s Form 10-Q for the quarterly period ended March 26, 2004, filed by AMO
with the Commission on May 3, 2004, also include information concerning these and other
risk factors. Copies of press releases and additional information about AMO are available
on the World Wide Web at www.amo-inc.com, or you can contact the AMO Investor Relations
Department by calling (714) 247-8348.  </FONT></TD></TR>
</TABLE>
<BR>



<!-- MARKER FORMAT-SHEET="Head Center 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=CENTER><FONT FACE="Arial, Helvetica, Sans-Serif" SIZE="2">#&nbsp;#&nbsp; #&nbsp;</FONT></TD></TR>
</TABLE>
<BR>


</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "la343267.htm", "secsgml_size_bytes": 23918}]
{"company-data": {"conformed-name": "ADVANCED MEDICAL OPTICS INC", "cik": "0001168335", "assigned-sic": "3841", "irs-number": "330986820", "state-of-incorporation": "DE"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-31257", "film-number": "04873535"}, "business-address": {"street1": "1700 E. ST. ANDREW PL.", "city": "SANTA ANA", "state": "CA", "zip": "92705", "phone": "714-247-8200"}}
8-K
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):  June 21, 2004
ADVANCED MEDICAL OPTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware
01-31257
33-0986820
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
1700 E. St. Andrew Place
Santa Ana, CA
92705
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including area code:
(714) 247-8200
(Former name or former address, if changed since last report)
Item 5.      Other Events and Regulation FD Disclosure.
On
June 21, 2004, Advanced Medical Optics, Inc. issued a press release, attached hereto as
Exhibit 99.1 and by this reference incorporated herein, announcing the results of
the previously announced consent solicitation for its 9¼% Senior Subordinated
Notes due 2010.
Item 7.      Financial Statements and Exhibits.
Exhibit
99.1       Press Release, dated June 21, 2004, issued by
Advanced Medical Optics, Inc.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
ADVANCED MEDICAL OPTICS, INC.
(Registrant)
Date:
June 21, 2004
By:
/s/ Aimee S. Weisner
Aimee S. Weisner
Corporate Vice President,
General Counsel and Secretary
EXHIBIT INDEX
Exhibit
No.
99.1
Press
Release, dated June 21, 2004, issued by Advanced Medical Optics, Inc.
Exhibit
99.1
FOR IMMEDIATE RELEASE
Investor Contact:
Sheree Aronson
(714) 247-8290
sheree.aronson@amo-inc.com
Media Contact:
Steve Chesterman
(714) 247-8711
steve.chesterman@amo-inc.com
ADVANCED MEDICAL OPTICS ANNOUNCES
RESULTS OF CONSENT SOLICITATION
RELATING TO ITS 9¼% SENIOR SUBORDINATED NOTES DUE 2010
(SANTA
ANA, CA), June 21, 2004 — Advanced Medical Optics, Inc. (AMO) [NYSE: AVO], today
announced that, as of 5:00 p.m., Eastern Daylight Time, on June 21, 2004 (the "Consent
Date"), it had received tenders and related consents from holders of approximately 99.99%
of the outstanding principal amount of its 9¼% Senior Subordinated Notes due 2010 (CUSIP number 00763MAC2)
(the "Notes") pursuant to its previously announced offer to purchase for cash
(the "Offer") any and all of the $70,000,000 outstanding principal amount of
the Notes and solicitation of consents to certain proposed amendments to the indenture
related to the Notes (the "Consent Solicitation"). The Consent Solicitation
expired on the Consent Date. Pursuant to its terms, the Offer will remain open until
12:00 midnight, Eastern Daylight Time, on July 8, 2004, unless extended or earlier
terminated (the "Expiration Time"). The Offer and the Consent Solicitation is
conditioned upon, among other things, the completion by AMO of financing transactions to
fund consummation of the Offer and the Consent Solicitation.
AMO
has received consents necessary to adopt the proposed amendments to the indenture related
to the Notes. Among other things, these amendments would eliminate substantially all of
the indenture's restrictive covenants and certain events of default contained in the
indenture. The supplemental indenture effecting the proposed amendments will become
operative on the Initial Payment Date, as described below.
Subject
to the terms and conditions of the Offer and the Consent Solicitation, AMO will pay the
"Total Consideration" to the holders who have validly tendered their Notes and
validly delivered their consents to the proposed amendments on or prior to the Consent
Date. Total Consideration will be determined based upon the pricing formula set forth in
the Offer to Purchase and Consent Solicitation Statement, dated June 9, 2004 (the "Statement"),
pursuant to which the Offer and the Consent Solicitation are being made, with June 22,
2004 being the price determination date. The Total Consideration includes a consent
payment of $30.00 per $1,000 principal amount of Notes (the "Consent Payment"),
and is payable on the applicable payment date.
Subject
to the terms and conditions of the Offer and the Consent Solicitation, AMO expects to
accept for payment and pay for all Notes that have been validly tendered and not validly
withdrawn on or prior to the Consent Date on or promptly following the first business day
after the Consent Date (the "Initial Payment Date"). AMO will pay to Holders
who validly tender their Notes after the Consent Date, but on or prior to the Expiration
Date, the Total Consideration minus the Consent Payment. Subject to the terms and
conditions of the Offer and the Consent Solicitation, AMO expects to accept for payment
and pay for all Notes that are validly tendered and not validly withdrawn after the
Consent Date, but on or prior to the Expiration Date, on or promptly following the first
business day after the Expiration Date (the "Final Payment Date"). In addition,
AMO may, at its option, elect to accept for payment, and pay for, Notes on interim
payment dates after the Initial Payment Date and before the Final Payment Date. Holders
will also be paid accrued and unpaid interest from the last interest payment date to, but
not including, the applicable payment date.
Holders
may not withdraw their tenders or revoke their consents at any time after the Consent
Date.
This
press release does not constitute an offer to purchase or the solicitation of an offer to
purchase, or a solicitation of consents with respect to the Notes. The Offer and the
Consent Solicitation may only be made in accordance with the terms and subject to the
conditions specified in the Statement and a related Letter of Transmittal and Consent,
which more fully set forth the terms and conditions of the Offer and Consent
Solicitation.
Lehman
Brothers Inc. is acting as the exclusive dealer manager and solicitation agent, Mellon
Investor Services LLC is acting as the information agent and The Bank of New York is
acting as depositary in connection with the Offer and the Consent Solicitation. Copies of
the Statement,, the Letter of Transmittal and Consent, and other related documents may be
obtained from the information agent at (877) 698-6865. Additional information concerning
the terms of the Offer and Consent Solicitation may be obtained by contacting Lehman
Brothers at (800) 438-3242 (toll free) and (212) 528-7581 (collect).
About
Advanced Medical Optics
Advanced
Medical Optics, Inc. is a global leader in the development, manufacturing and marketing
of ophthalmic surgical and eye care products. The company focuses on developing a broad
suite of innovative technologies and devices to address a wide range of eye disorders.
Products in the ophthalmic surgical line include foldable intraocular lenses,
phacoemulsification systems, viscoelastics and related products used in cataract surgery,
and microkeratomes used in LASIK procedures for refractive error correction. AMO owns or
has the rights to such ophthalmic surgical product brands as PhacoFlex®, Clariflex®,
Array® and Sensar® foldable intraocular lenses, the Sovereign® phacoemulsification
system with WhiteStar™ technology and the Amadeus™ microkeratome. Products in
the contact lens care line include disinfecting solutions, daily cleaners, enzymatic
cleaners and lens rewetting drops. Among the contact lens care product brands the company
possesses are COMPLETE®, COMPLETE® Blink-N-Clean®, COMPLETE® Moisture PLUS™,
Consept®F, Consept® 1 Step, Oxysept® 1 Step, Ultracare®, Ultrazyme®,
Total Care® and blink™ branded products. Amadeus is a licensed product of, and a
trademark of, SIS, Ltd.
Advanced
Medical Optics, Inc. is based in Santa Ana, California, and employs approximately 2,300
worldwide. The Company has direct operations in about 20 countries and markets products
in approximately 60 countries. For more information, visit the Company's web site at
www.amo-inc.com.
Forward-Looking Statements
This
press release contains forward-looking statements about AMO, including those relating to
the terms of the Offer and the Consent Solicitation and whether or not AMO will
consummate the Offer and the Consent Solicitation. All forward-looking statements in this
press release are based on estimates and assumptions and represent AMO's judgment
only as of the date of this press release. Actual results may differ from current
expectations based on a number of factors including but not limited to changing market
conditions and AMO's ability to raise sufficient funds to complete the financing to
fund the Offer and the Consent Solicitation. In addition, matters generally affecting the
domestic and global economy, such as changes in interest and currency exchange rates, can
affect AMO's results. Therefore, the reader is cautioned not to rely on these
forward-looking statements. AMO disclaims any intent or obligation to update these
forward-looking statements.
Additional
information concerning these and other risk factors may be found in previous financial
press releases issued by AMO. AMO's public periodic filings with the Securities and
Exchange Commission, including the discussion under the heading "Certain Factors and
Trends Affecting AMO and its Businesses" in AMO's 2003 Form 10-K filed by AMO
with the Securities and Exchange Commission (the "Commission") on March 12,
2004 and AMO's Form 10-Q for the quarterly period ended March 26, 2004, filed by AMO
with the Commission on May 3, 2004, also include information concerning these and other
risk factors. Copies of press releases and additional information about AMO are available
on the World Wide Web at www.amo-inc.com, or you can contact the AMO Investor Relations
Department by calling (714) 247-8348.
# #  #